Inhibikase Therapeutics (IKT)

• Market cap: $116M
• 1 day: -2.5%
• 5 days: -4.88%
• 1 month: -9.3%
• 3 months: -19.59%
• 6 months: -33.9%
• Year to date: -52.58%
• 1 year: 34.48%
• 5 years: -97.37%
• 10 years: -97.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Employees: 16

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

4.1% more ownership

Funds ownership: 69.23% [Q1] → 73.33% (+4.1%) [Q2]

2% more funds holding

Funds holding: 47 [Q1] → 48 (+1) [Q2]

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

6% less capital invested

Capital invested by funds: $113M [Q1] → $106M (-$6.4M) [Q2]